On November 4, 2026 Immix Biopharma, Inc. ("Immix", "Company", "We" or "Us" or "IMMX"), a global leader in AL Amyloidosis, reported that it will present an NXC-201 abstract at the upcoming American Society of Hematology (ASH) (Free ASH Whitepaper) 68th Annual Meeting and Exposition to be held December 12-15, 2026, in New Orleans, LA.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ASH Oral Presentation Details:
Event 68th ASH (Free ASH Whitepaper) Annual Meeting and Exposition, New Orleans, LA
Title "45-patient safety and efficacy data for NXC-201 from Nexicart-2, the first U.S. trial of CAR-T in relapsed/refractory AL amyloidosis"
Presentation
Date/Time (Central Time)
Publication #826
Session Date: Monday, December 14, 2026
Session Name: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Advancing Treatment Strategies in AL Amyloidosis
Session Time: 10:30 AM -12:00 PM
Presentation Time: 11:15 AM
About AL Amyloidosis
Amyloid light-chain (AL) amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead continuously produces toxic light chains that build up in organs including the heart, kidney, and liver, causing organ failure and death.
AL amyloidosis is the most common form of amyloidosis according to the National Institutes of Health. The number of patients in the U.S. with relapsed/refractory AL Amyloidosis is estimated to be growing at 12% per year according to Staron, et al Blood Cancer Journal, to approximately 30,506 patients in 2026.
The Amyloidosis market was $6.2 billion in 2025, and is expected to reach $6.6 billion in 2026, according to Grand View Research.
(Press release, Immix Biopharma, NOV 4, 2026, View Source [SID1234674169])